Personalized radiation therapy shows promise for slowing neuroendocrine tumors
NCT ID NCT02743741
First seen Jan 11, 2026 · Last updated May 14, 2026 · Updated 17 times
Summary
This study tests a radioactive drug called Lu-DOTATATE in people with neuroendocrine tumors that have a specific marker (somatostatin receptors). The treatment delivers radiation directly to tumor cells, and the dose is adjusted for each patient. The goal is to see if it can stop or slow tumor growth. About 195 people from Ontario are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Juravinski Cancer Centre
Hamilton, Ontario, Canada
-
London Health Sciences Centre
London, Ontario, Canada
-
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
-
Sunnybrook Odette Cancer Center
Toronto, Ontario, Canada
Conditions
Explore the condition pages connected to this study.